About this trial
It is planned to include 10000 patients. In the China HeadAche DIsorders RegiStry CHAIRS), patients aged over 12 years with primary headache and medication-overuse headache(MOH) were collected. The biomarkers, imaging features, cognition, genetic characteristics, ocial and demographic data, medical data, therapeutics used, and outcome of headache-related diseases were studied, and long-term follow-up was planned.
Eligibility criteria
Qualifiers
Age ≥ 12 years old,Any gender;
The first onset age of primary headache was less than 50 years old(Age <65 years at first diagnosis of chronic migraine);
patients with primary headache (migraine, tension headache and other types of primary headache) or primary headache complicated with MOH according to ICHD-3;
Sign the informed consent form.
Disqualifiers
According to the ICHD-3 diagnostic criteria, there are still headaches directly related to secondary factors (except drug overuse) at the time of enrollment;
Those who cannot be diagnosed as primary headache or primary headache combined with medication overuse headache according to ICHD-3;
According to DSM-V diagnostic criteria, patients with severe mental diseases (such as schizophrenia, mental disorders associated with mental retardation, etc.);
Patients with severe organic diseases, such as malignant tumors, and the expected survival time is less than 1 year;
Trial design
Treatments tested in this trial
- Medicine Overuse Headache/New Daily Persistent Headache
- Episodic Migraine and Chronic Migraine
- Patients with other types of primary headache
- Yangxue Qingnao Granules (Pills)
- Erenumab
- Eptinezumab